shstuebingen Current page: 22

The Börsen-Zeitung covers the publication of the SHS-Medtech-Index and reports on new developments in the industry, with the Medical Device Regulation being a crucial topic. In light of stagnant numbers of patent approvals per year in the Medtech industry, Hubertus Leonhardt is cited by the newspaper. The Managing Partner of SHS states that there is […]

Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO® Impulse System for treatment of STEMI patients. The FDA Breakthrough Device designation is intended to speed time to market for treatments of life-threatening or irreversibly debilitating diseases or conditions and recognizes the novelty […]

The Frankfurter Allgemeine Zeitung reports about the newly issued SHS-Medtech-Index, which was jointly developed by Christian Koziol, Head of the Finance Department of the University of Tübingen, and SHS. The index measures the development of the German Medtech industry in relation to the overall economy since 2010. Four indicators are used: revenue, working population, patents […]

Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology.

Die Basler Zeitung berichtet über eine Weltpremiere: Die erste Operation, bei der menschlicher Knochen ausschließlich mit einem robotergesteuerten Laser geschnitten wurde. Philipp Jürgens, leitender Arzt in der Mund-, Kiefer- und Gesichtschirurgie am Universitätsspital Basel, sieht das Potenzial „die Knochenchirurgie zu revolutionieren“. Das innovative Verfahren basiert auf Carlo, einem Laser-Osteotomie Roboter, entwickelt vom SHS-Portfoliounternehmen AOT. Carlo […]

The Venture Capital magazine examines the price level of buyout transactions this spring, with a special focus on medical technology. Experts classify the industry as very promising, but rate the prices as often not justified. Hubertus Leonhardt, Managing Partner at SHS Gesellschaft für Beteiligungsmanagement mbH, points out that buyout transactions are often about more than […]

WirtschaftsWoche reports on the third investment of SHS from its current fund SHS V. Betterguards Technology GmbH, founded in 2014 and headquartered in Berlin with a production facility in Brandenburg, develops and produces intelligent components (so-called adaptors) that can be integrated into sports shoes, bandages or work protection shoes, for example. Equipped with this unique […]

Third investment from fifth SHS fund – development of a diversified portfolio of medical technology and life science companies TTübingen-based medical technology investor SHS Gesellschaft für Beteiligungsmanagement mbH has invested a mid single-digit million amount from its fifth fund in Betterguards Technology GmbH. The technology developed and produced by the Berlin-Brandenburg-based company is primarily aimed […]

c-LEcta, an innovative SHS portfolio company in the field of white biotechnology, reports in the Süddeutsche Zeitung on how its enzymes are used to produce new sweeteners based on the stevia plant. The sweeteners developed jointly with industrial partners already have FDA approval in the USA, where sugar substitutes are used in beverages and food. […]

The private equity news portal Unquote evaluates the effects of the new German Scheduling and Supply Act and refers to the opportunities and risks of the global medical technology market. Despite tougher regulations, experts do not expect an economic slowdown for the medical technology, life science and biotechnology industries. Dr. Andre Zimmermann, Partner at SHS […]

The concept with which the Graz-based company Tyromotion made it from university to world market leader is taken up in “die wirtschaft”. The SHS portfolio company from the SHS IV fund develops robotic and computer-supported therapy devices that support patients in rehabilitation after a stroke, multiple sclerosis or spinal cord injury. Tyromotion uses a playful […]

The SHS V fund managed by Tübingen-based SHS Gesellschaft für Beteiligungsmanagement has acquired a joint stake in Swiss evitria AG together with AFINUM. The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. For SHS, it is the first investment from its SHS V fund, which had its first […]